<DOC>
	<DOCNO>NCT02012920</DOCNO>
	<brief_summary>The goal clinical study determine safety , tolerability , pharmacokinetics activity VT-464 , lyase-selective inhibitor CYP17 , patient castration-resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>A Study Evaluate Oral VT-464 Patients With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This Phase 1/2 study VT-464 treatment-naïve patient CRPC CRPC patient fail prior therapy abiraterone , enzalutamide , and/or chemotherapy . The study consist 2 phase : dose-escalation phase ( Phase 1 ) cohort-expansion phase ( Phase 2 ) . Phase 1 open-label , multicenter , sequential-dose cohort design treatment-naive patient Phase 2 open-label , multicenter , parallel-group design treatment-naive treatment-failure patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Key Patients must document histological cytological evidence adenocarcinoma prostate . Patients must minimum serum PSA level &gt; 2 ng/ml rise base Prostate Cancer Working Group 2 criterion . Patients must castrate level testosterone ( &lt; 50 ng/dl [ 1.74 nmol/l ] ) . Patients must undergo orchiectomy , LHRH agonists antagonist , least 3 month prior study entry . Patients LHRH agonists/antagonists must remain agent duration study . Patients must ECOG Performance Score 0 1 . Key Patients receive prior cytotoxic chemotherapy prostate cancer unless enrol previous chemotherapy cohort . Patients receive secondline antihormonal therapy , include ketoconazole , aminoglutethimide , highdose estrogen within 30 day study entry . Patients complete sipuleucelT ( Provenge ® ) treatment within 30 day study entry . Patients receive abiraterone ( Zytiga® ) , TAK700 ( Orteronel® ) , TOK001 ( Galeterone® ) , MDV3100 , investigational product direct towards androgen receptor androgen biosynthesis . Previous abiraterone enzalutamide allow certain treatmentfailure cohorts Patients receive antiandrogens flutamide ( EULEXIN® ) , bicalutamide ( CASODEX® ) , nilutamide ( NILANDRON® ) &gt; 3 month must treatment 6 week demonstrate continue rise PSA withdrawal . Patients antiandrogens &lt; 3 month must medication 2 week . Patients 5 alpha reductase inhibitor finasteride ( PROSCAR® , PROPECIA® ) , dutasteride ( AVODART® ) must stop medication least 3 month study entry . Patients require pharmacological replacement dos systemic corticosteroid receive systemic corticosteroid within 30 day study entry ; use topical , inhaled ophthalmic steroid permit . Patients receive palliative radiotherapy within 4 week study entry . Patients history within last 3 year another invasive malignancy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>castration-resistant prostate cancer</keyword>
	<keyword>CYP17</keyword>
	<keyword>P450c17a</keyword>
	<keyword>lyase</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>